Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

3.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

3.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
3.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

846
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
846

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same author

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Blood cancer journal·2026
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.

Haematologica·2026

Related Experiment Video

Updated: Jun 5, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K

Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas.

Robert Stuver1, Steven M Horwitz1,2

  • 1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Hematology. American Society of Hematology. Education Program
|December 7, 2024
PubMed
Summary

Advanced cutaneous T-cell lymphomas (CTCLs) like mycosis fungoides/Sézary syndrome (MF/SS) have new systemic therapies. Aggressive CTCLs, including PCAETCL and PCGDTCL, need further research for targeted, biomarker-driven treatments.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.7K

Related Experiment Videos

Last Updated: Jun 5, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.7K

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Cutaneous T-cell lymphomas (CTCLs) present a spectrum of disease severity, from indolent to aggressive forms with systemic spread.
  • Aggressive CTCL subtypes, including advanced mycosis fungoides/Sézary syndrome (MF/SS), primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETCL), and primary cutaneous gamma delta T-cell lymphoma (PCGDTCL), necessitate systemic treatment.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for aggressive CTCLs, focusing on MF/SS and highlighting the need for advancements in PCAETCL and PCGDTCL.
  • To discuss the integration of compartmental efficacy and combination therapies in MF/SS management.
  • To explore the potential of biomarker-driven therapeutic approaches for PCAETCL and PCGDTCL.

Main Methods:

  • Review of recent literature and clinical trial data on CTCL treatment options.
  • Analysis of evolving management strategies for MF/SS, incorporating insights into drug efficacy across different body compartments.
  • Examination of recent genomic findings in PCAETCL and PCGDTCL to identify potential therapeutic targets.

Main Results:

  • Treatment options for MF/SS have significantly expanded over the past five years, driven by biological insights and leading to novel systemic therapies.
  • Current MF/SS management incorporates an understanding of compartmental drug efficacy and explores combination modalities for durable responses.
  • Limited prospective studies exist for PCAETCL and PCGDTCL, but recent genomic discoveries, such as JAK2 fusions in PCAETCL, offer promise for targeted therapies.

Conclusions:

  • Systemic therapy is crucial for aggressive CTCLs, with notable advancements in MF/SS treatment paradigms.
  • Future directions for PCAETCL and PCGDTCL involve leveraging genomic insights to develop biomarker-guided therapeutic strategies.
  • Continued research is essential to improve outcomes for all aggressive CTCL subtypes.